BTG, a specialist healthcare company, has reported that its VANISH-1 and VANISH-2 studies have 'demonstrated efficacy in achieving a clinically meaningful improvement' in the appearance of the legs of patients with varicose veins.
The studies found that 80% of patients treated with either the 0.5% or 1.0% dose concentrations reported a much or moderate improvement of symptoms.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dr Kenneth Todd, a Principal Investigator for VANISH-2 said: "Current treatments for patients with medically-important, symptomatic varicose veins are time-consuming for both patients and physicians and do not offer a comprehensive treatment.
"The publication of the full results for VANISH-1 and VANISH-2 confirm the top-line results already reported and demonstrate that the product, if approved, could offer an effective, comprehensive treatment option for patients with symptomatic varicose veins."
NR
-
73% of savers plan to rely on partner’s pension in retirementA new survey suggests the majority of people may lack financial independence in retirement, with almost three-quarters set to rely on their partner’s pension
-
How much you need to follow the 25x retirement rule – will you have enough to be financially independent?We explain what the 25x retirement rule is and the amount you would need to be financially independent in retirement.
